title: Evaluation of a new foam to increase skin hydration of the foot in type 2 diabetes: a pilot study.
abstract: The aim of the present study was to evaluate the efficacy of a new product (Neuropad repair foam(®)) in promoting skin hydration of the foot in type 2 diabetes. Included in this study were 20 type 2 diabetic patients (10 men, mean age 61·40 ± 2·44 years). Patients applied Neuropad repair foam(®) on the plantar aspect of the right foot twice daily. No agent was applied on the left foot. Patients were examined at baseline, after 7 treatment days and after 14 treatment days. Evaluation of skin dryness was performed by means of the Multi Skin test Corneometer MC 900. In the right foot, skin capacitance was 26·55 ± 4·14 arbitrary units (a.u.) at baseline, 28·90 ± 4·53 a.u. after 7 days of treatment and 32·05 ± 4·54 a.u. after 14 days of treatment. There was a significant increase in skin capacitance from baseline to 7 days of treatment (P < 0·001), from baseline to 14 treatment days (P < 0·001), as well as from 7 to 14 days of treatment (P < 0·001). The same significant (P < 0·001) increases were observed both in men and in women. No changes were noted in the left foot. At baseline, there was no difference in skin capacitance between right and left foot (P = 0·186). However, skin capacitance was significantly higher on the right versus left foot, both after 7 days (P < 0·001) and after 14 days of treatment (P < 0·001). In conclusion, results with the new foam appear encouraging in ameliorating skin dryness in the diabetic foot and further investigation is warranted.
authors: Outpatient Clinic of the Diabetic Foot, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece. papanasnikos@yahoo.gr
authors: Nikolaos
authors: N
authors: Papanas
authors: Dimitrios
authors: D
authors: Papazoglou
authors: Konstantinos
authors: K
authors: Papatheodorou
authors: Efstratios
authors: E
authors: Maltezos
mesh_terms: D001458:Bandages; D001672:Biocompatible Materials; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy; D017719:Diabetic Foot / Q000175:diagnosis* / Q000628:therapy*; D005260:Female; D005339:Fibrin Foam / Q000494:pharmacology*; D005500:Follow-Up Studies; D006801:Humans; D055103:Hypodermoclysis / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D018570:Risk Assessment; D012720:Severity of Illness Index; D012869:Skin Absorption / Q000502:physiology; D014945:Wound Healing / Q000502:physiology*
chemical_list: D001672:Biocompatible Materials; D005339:Fibrin Foam